Form 4: Medpace CEO Sells 620 Shares in Pre-Planned Transaction

Medpace Holdings, Inc. CEO August J. Troendle sold 620 shares of common stock at $475 per share, executed under a pre-arranged trading plan.

Summary

• August J. Troendle, CEO, Director, and 10% Owner of Medpace Holdings, Inc. (MEDP), sold 620 shares of common stock.
• The transaction occurred on August 27, 2025, at a price of $475 per share.
• The sale was executed pursuant to a limit order placed by the Reporting Person during an open window period, indicating a pre-planned transaction.
• Following the transaction, Mr. Troendle directly beneficially owns 961,995 shares of common stock.
• Additionally, he indirectly beneficially owns 4,733,019 shares through Medpace Investors, LLC, where he is the sole manager and controlling unit holder.

Sentiment

Score: 5

Explanation: A score of 5 indicates a neutral to slightly negative sentiment. While insider selling can be viewed negatively, the transaction being part of a pre-planned limit order mitigates the negative signal, suggesting it's not necessarily a reaction to new adverse information.

Positives

• NA

Negatives

• Insider selling by a CEO and 10% owner, even if pre-planned, can sometimes be perceived negatively by the market as it reduces management's direct equity stake.

Risks

• NA

Future Outlook

NA

Management Comments

• The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period.
• The Reporting Person is the sole manager and controlling unit holder of Medpace Investors, LLC ("MPI") and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Industry Context

NA

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• August J. Troendle indirectly beneficially owns 4,733,019 shares through Medpace Investors, LLC, where he serves as the sole manager and controlling unit holder. He disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.

Stakeholder Impact

• Shareholders: May interpret the insider sale as a slight negative signal, although the pre-planned nature (limit order) suggests it's not based on new, adverse information.

Next Steps

• NA

Key Dates

Recommendation

The sale of 620 shares by CEO August J. Troendle, while a reduction in his direct holdings, appears to be a routine transaction executed via a pre-planned limit order. This suggests the sale is not necessarily indicative of a change in the company's fundamental outlook or a lack of confidence. Investors should consider this transaction in the broader context of the CEO's substantial remaining direct and indirect holdings and the company's overall performance, rather than as a standalone signal for a 'sell' recommendation. A 'hold' recommendation is appropriate as this single transaction does not provide sufficient new information to alter a long-term investment thesis.

Keywords

Medpace Holdings, MEDP, August J. Troendle, Insider Sale, Form 4, CEO, Stock Transaction, 10b5-1 Plan